Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00718627
Other study ID # CCD02
Secondary ID CCD022006-000136
Status Completed
Phase Phase 2
First received July 16, 2008
Last updated February 5, 2016
Start date July 2008
Est. completion date November 2015

Study information

Verified date February 2016
Source Cytonet GmbH & Co. KG
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

Urea cycle disorders are rare inherited diseases that generally have a poor outcome. In this study, neonates and infants with UCD will be included within the first 3 months of life and will be treated by repetitive application of human liver cells to reduce the risk of neurological deterioration while awaiting OLT.


Description:

Urea cycle disorders are rare inherited diseases that generally have a poor outcome, especially with onset of the disease in the neonatal period. UCDs are caused by a deficiency of one of six enzymes responsible for removing ammonia from the bloodstream. Instead of being converted into urea which is removed from the body with the urine, ammonia accumulates in UCD patients leading to brain damage or death. In the light of a mortality rate of > 50% at the age of 10 years the current pharmacological and dietary therapy is of modest success. Furthermore, mental retardation, cerebral palsy and other neurological sequelae are common among surviving patients.

In the last years, orthotopic liver transplantation (OLT) has become the best therapeutic option for UCD with long-term survival rates of about 90%. However, in the first weeks of life OLT still is technically demanding and prone to complications. With larger size of the recipient, the technical problems with OLT decrease considerably. The increased body weight usually achieved at the age of more than 8 weeks is related to a major reduction in transplantation related morbidity. Stabilization of metabolism until the patient can undergo OLT is essential.

In this study, neonates and infants with UCD will be included within the first 3 months of life and will be treated by repetitive application of human liver cells. In the last consequence, the aim of this new therapy option is to supply a sufficient amount of healthy liver cells to compensate for the metabolic defect and to reduce the risk of neurological deterioration while awaiting OLT.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender Both
Age group N/A to 5 Years
Eligibility Inclusion Criteria

- Neonates and infants up to the age of = 3 months with prenatally or postnatally confirmed urea cycle disorder and

- Children aged > 3 months up to = 5 years of age with unstable metabolism and confirmed urea cycle disorder of either:

- Carbamylphosphate synthetase I [CPSD] or

- Ornithine transcarbamylase [OTCD] or

- Argininosuccinate synthetase [Citrullinaemia]

- A DNA analysis will further confirm diagnosis prior to or after inclusion according to the protocol.

- Accessibility of the portal vein

- Plasma ammonia level = 250 µmol/l

- Written informed consent

Exclusion Criteria

- Structural liver disease (cirrhosis, portal hypertension), or venoocclusive diseases

- Portal vein thrombosis

- Body Weight =3.5 kg

- Carrier of the human immuno-deficiency virus (HIV)

- Any other contraindication for immunosuppression

- Presence of acute infection at the time of inclusion

- Participation in other clinical trials or received experimental medication within the last 30 days

- Live vaccination planned during the course of the study

- Live vaccination within 4 weeks prior to beginning of study

- Allergic disposition against contrast medium used in study and/or antibiotics used in the manufacturing process

- Required valproate therapy

- Severe coagulopathy or thrombocytopenia

- Known diagnosis of hereditary thrombophilia (e.g. Factor V Leiden, Prothrombin 20210A variant) or parental history of hereditary thrombophilia and absense of thrombophilia testing in subject

- Cancer, severe systemic or chronic disease other than study indication (urea cycle deficiency)

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Human Heterologous Liver Cells
Multiple applications of liver cell suspension for infusion

Locations

Country Name City State
Germany University Children's Hospital, Heinrich-Heine University Düsseldorf
Germany University Children's Hospital Heidelberg

Sponsors (1)

Lead Sponsor Collaborator
Cytonet GmbH & Co. KG

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of the application of liver cells, safety of the placement of an application catheter to the portal vein. 7 - 15 weeks Yes
Secondary Changes in 13C urea formation. Changes in the respective enzyme activity in liver biopsies from the explanted organ compared to the enzyme activity in the liver before cell application. 7-15 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT02252770 - Nitric Oxide Supplementation in Argininosuccinic Aciduria N/A
Completed NCT01002469 - Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment N/A
Completed NCT00986895 - A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group Phase 1
Completed NCT01257737 - To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs) Phase 4
Recruiting NCT05671666 - Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients N/A
Completed NCT02311283 - Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment N/A
Completed NCT02489292 - Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002) Phase 2
Completed NCT00992459 - Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders Phase 3
Completed NCT00551200 - Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders Phase 2
Completed NCT00947297 - Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD) Phase 3
Completed NCT02740153 - PCORI Urea Cycle Disorder Study
Completed NCT02051049 - Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
Completed NCT01765283 - Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Phase 1/Phase 2
Completed NCT00947544 - Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders Phase 2
Completed NCT01347073 - Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs) Phase 3
Completed NCT03797131 - Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Disorders N/A
Completed NCT01549015 - Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function N/A
Terminated NCT01541722 - Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders N/A
Completed NCT00345605 - Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder Phase 2
Recruiting NCT00237315 - Longitudinal Study of Urea Cycle Disorders